Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push

Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion to enhance its portfolio in cell therapy, targeting advancements in treatments for autoimmune disease and RNA technology.

• Bristol Myers Squibb announced its acquisition of Orbital Therapeutics for $1.5 billion on a cash basis, aimed at strengthening its position in the competitive cell therapy market.
• The deal will allow Bristol Myers Squibb to integrate Orbital Therapeutics innovative approaches to cell therapy, particularly those utilizing RNA technology for potential treatments of autoimmune disease.
• With this acquisition, Bristol Myers Squibb seeks to diversify its product offerings as it faces increasing competition from generic drugs affecting its legacy products.